semaglutide 2.4 mg obesity weekly Efficacy and safety of once-weekly 2·4 versus placebo in people with and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial Semaglutide 2.4 mg Injection at Semaglutide Shines as Weight Loss

Safety Considerations and Monitoring for Young Adults on GLP-1s GLP-1 medications are generally well-tolerated, but nausea, vomiting, and constipation occur commonly during dose initiation and escalation

Always consult a provider, as responses vary based on individual health, and ongoing research refines long-term use

Future validation in larger multicenter cohorts is needed, with full multivariable adjustment and inclusion of short-chain acyl-carnitines (C4C6) to assess their added predictive value

Final Considerations Most insurance plans cover Ozempic for type 2 diabetes but are less likely to cover it for weight loss

Theyre made of plastic and should be discarded after one use

Fermentation of Fiber Beneficial gut bacteria break down dietary fiber into short-chain fatty acids (SCFAs), such as butyrate and propionate